These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37680472)

  • 21. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Arnold DD; Yalamanoglu A; Boyman O
    Front Immunol; 2022; 13():888392. PubMed ID: 35874710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
    Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts.
    Kawaguchi Y; McCarthy SA; Watkins SC; Wright TM
    J Rheumatol; 2004 Oct; 31(10):1946-54. PubMed ID: 15468358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
    Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
    Rabe KF; Celli BR; Wechsler ME; Abdulai RM; Luo X; Boomsma MM; Staudinger H; Horowitz JE; Baras A; Ferreira MA; Ruddy MK; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
    Lancet Respir Med; 2021 Nov; 9(11):1288-1298. PubMed ID: 34302758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.
    Khanna D; Tashkin DP; Wells AU; Seibold JR; Wax S; Vazquez-Mateo C; Fleuranceau-Morel P; Damian D; Denton CP
    J Rheumatol; 2021 Aug; 48(8):1295-1298. PubMed ID: 33004536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis.
    Fukayama M; Yoshizaki A; Fukasawa T; Ebata S; Kuzumi A; Yoshizaki-Ogawa A; Asano Y; Oba K; Sato S
    J Dermatol; 2020 Nov; 47(11):1287-1292. PubMed ID: 32686186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
    Seibold JR; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells A; Matucci Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM
    Arthritis Rheum; 2010 Jul; 62(7):2101-8. PubMed ID: 20506355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
    Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
    Borrirukwisitsak S; Tantayakom P; Katchamart W
    Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.
    Kawaguchi Y; Harigai M; Hara M; Fukasawa C; Takagi K; Tanaka M; Tanaka E; Nishimagi E; Kamatani N
    J Rheumatol; 2002 Sep; 29(9):1877-83. PubMed ID: 12233882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
    Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
    Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.